Open AccessCOVID-19 in Patients with Atopic Dermatitis Treated with Dupilumab: Three Cases and a Literature Review
Author(s) -
Justyna Ceryn,
Michał Niedźwiedź,
Małgorzata Skibińska,
Magdalena Ciążyńska,
Aleksandra Lesiak,
Joanrbutt
Publication year - 2021
Publication title -
clinical, cosmetic and investigational dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 35
ISSN - 1178-7015
DOI - 10.2147/ccid.s321003
Subject(s) - dupilumab , atopic dermatitis , scorad , medicine , dermatology , covid-19 , interleukin 17 , immunology , monoclonal antibody , antibody , disease , cytokine , dermatology life quality index , infectious disease (medical specialty) , psoriasis
There are limited clinical data on the impact of the SARS-CoV2 infection on patients with dermatological conditions treated with biologics. Dupilumab is a recombinant human IgG 4 human monoclonal antibody that inhibits IL4 and IL13 signaling, and is used for moderate-severe atopic dermatitis treatment. We present three patients with atopic dermatitis (AD) treated with dupilumab who contracted COVID-19. In all patients, the infection had a mild course, and only in one, as documented by SCORAD, EASI, and DLQI scores, the condition of the skin deteriorated, and a prolonged positive PCR COVID-19 test was observed. The mechanism of dupilumab action and more evidence for IL13 importance in lung damage caused by SARS-CoV2 suggest a possible explanation for a mild-moderate course of the infection in treated AD patients. Based on current knowledge, there is evidence to continue dupilumab treatment in AD patients with mild-moderate COVID-19; however, careful assessment is needed for each patient.